Proteasome Inhibitors Market by Product and Geography - Global Forecast 2019-2023

Global Proteasome Inhibitors Market: About this market

Proteasome inhibitors are used for the treatment of multiple myeloma. proteasome inhibitors market analysis considers sales from VELCADE, KYPROLIS, NINLARO, and other products segments. Our analysis also considers the sales of proteasome inhibitors in Asia, Europe, North America, and ROW. In 2018, the VELCADE segment held the highest market share, which is expected to remain prevalent over the forecast period. The drug is the first proteasome inhibitor to receive approvals from the FDA and EMA. Moreover, the drug is the most effective in treating multiple myeloma. These factors will significantly help the VELCADE segment in maintaining its leading market position. Also, our global proteasome inhibitors report has observed market growth factors such as the huge unmet need, strong adoption rate, and growing incidence of myeloma. However, the threat from biologics, strong adverse effects, and slow regulatory approval may hamper the growth of the proteasome inhibitors industry over the forecast period.

Global Proteasome Inhibitors Market: Overview

Huge unmet need

There is a significant unmet treatment need for myeloma and a few solid tumor indications. Vendors are leveraging this situation and are focusing on developing therapeutics for the same. The market also has only a few approved therapies. As a result, there is significant scope for vendors to expand into the market. Therefore, the huge unmet need and the rising incidence of cancer will propel the growth of the global proteasome inhibitors market over the forecast period. The market is expected to record a CAGR of about 8% during the forecast period.

Expanded application

Apart from treating myeloma and solid tumors, proteasome inhibitor drugs are also being used to cure non-oncology conditions. For instance, ACU-D1 is a novel proteasome inhibitor that is proven to treat rosacea. The drug is in its second phase of clinical studies. There is ongoing research on expanding applications of proteasome inhibitor drugs to treat other conditions. This factor will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global proteasome inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global proteasome inhibitors market is concentrated. robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors producers, which include Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Frequently Asked Questions



This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

  • By product type
  • By End User/Applications
  • By Technology
  • By Region

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Please Select a Format

market Reports market Reports